

3002638 SARS-CoV-2 (COVID-19) by NAA
 Changes Effective 6/17/2020

COVID19NAA



Patient Demographics Form for Public Health Reporting



Specimen Collection and Handling



Additional Technical Information

Methodology: Qualitative Nucleic Acid Amplification
Performed: Daily
Reported: 1-4 days

Specimen Required: Collect: Nasopharyngeal swab. Also acceptable: Oropharyngeal or Nasal swab.
 Refer to https://ltd.aruplab.com/api/ltd/pdf/479?_ga=2.1847542.611705577.1589487387-1588029776.1584652665
Specimen Preparation: **Nasopharyngeal swab:** Place in viral transport media, Liquid Amies, or saline (minimum volume 1.2 mL). Place each specimen in an individually sealed bag.
Oropharyngeal or nasal swab: Place in viral transport media, Liquid Amies, or saline (minimum volume 1.2 mL). Or collect using the Aptima Multitest Swab Collection Kit. Place each specimen in an individually sealed bag.
 Also acceptable: Media that is equivalent to viral transport media or universal transport media.
Storage/Transport Temperature: Frozen
Remarks: Specimen source required.
Unacceptable Conditions: Wood swabs, calcium alginate swabs.
Stability (collection to initiation of testing): Ambient: Unacceptable; Refrigerated: 2 days; Frozen: 1 month

Interpretive Data: This test should be ordered for the detection of the 2019 novel coronavirus SARS-CoV-2 in individuals who meet SARS-CoV-2 clinical and/or epidemiological criteria.

The Coronavirus SARS-CoV-2 (COVID-19) by nucleic acid amplification test is for in vitro diagnostic use under the FDA Emergency Use Authorization (EUA) for US laboratories certified under CLIA to perform high complexity tests. This test has not been FDA cleared or approved. In compliance with this authorization, please visit <https://www.aruplab.com/infectious-disease/coronavirus> for more information and to access the applicable information sheets.

If the result is Not Detected, this does not rule out the presence of PCR inhibitors in the patient specimen or assay specific nucleic acid in concentrations below the level of detection by the assay.

CPT Code(s): U0003; (Alt code: 87635)

New York DOH Approved.

HOTLINE NOTE 6/17/2020: There is an increase in the minimum transport volume.	Increase minimum transport volume to 1.2 mL.
HOTLINE NOTE 5/18/2020: There is a clinically significant charting name change.	Change the charting name for component 3002640, to SARS-CoV-2 by NAA.